Skip to main content

Table 2 Characteristics of hepatocellular adenoma (HCA) subtypes

From: Differentiation of hepatocellular adenoma by subtype and hepatocellular carcinoma in non-cirrhotic liver by fractal analysis of perfusion MRI

 

All HCA (n = 47)

H-HCA (n = 13)

b-HCA (n = 7)

I-HCA (n = 27)

P value

Women (%)

43 (92)

12 (92)

5 (71)

26 (96)

.11

Age (years) ± SD (range)

35 ± 7 (18–57)

37 ± 8 (18–57)

32 ± 8 (22–51)

35 ± 6 (24–47)

.38

BMI (kg/m2) ± SD

26 ± 3

24 ± 2

25 ± 2

27 ± 3

.62

Oral estrogen intakea (%)

23 (53)

5 (42)

3 (60)

15 (58)

.56

Previous pregnancya (%)

13 (30)

7 (58)

0 (0)

6 (23)

.03

Menopausea (%)

1 (2)

1 (8)

0 (0)

0 (0)

.27

Metabolic syndrome (%)

5 (11)

1 (8)

0 (0)

4 (15)

.56

Days between MRI and histology ± SD (range)

43 ± 25 (0–90)

43 ± 30 (0–90)

60 ± 21 (2–90)

39 ± 25 (0–89)

.28

Lesion size (mm) ± SD (range)

58 ± 25 (20–143)

60 ± 20 (25–143)

73 ± 29 (38–125)

54 ± 25 (20–140)

.21

Surgical resection (%)

14 (30)

2 (15)

5 (72)

7 (26)

.03

Presence of hepatic steatosis (%)b

16 (34)

1 (8)

1 (14)

14 (52)

.01

Presence of intralesional fat (%)b

17 (36)

12 (92)

4 (57)

1 (4)

 < .001

MRI features (%)

     

 Arterial phase

     

  Hyperintense

38 (81)

8 (62)

5 (71)

25 (93)

.05

  Isointense

7 (15)

4 (31)

1 (14)

2 (7)

.15

  Hypointense

2 (4)

1 (8)

1 (14)

0 (0)

.42

 Portal venous phase

     

  Hyperintense

24 (51)

0 (0)

1 (14)

23 (85)

 < .001

  Isointense

8 (17)

2 (15)

3 (43)

3 (11)

.14

  Hypointense

15 (32)

11 (85)

3 (43)

1 (4)

 < .001

 Delayed phase

     

  Hyperintense

22 (47)

0 (0)

1 (14)

21 (78)

 < .001

  Isointense

6 (13)

0 (0)

2 (29)

4 (15)

.33

  Hypointense

19 (40)

13 (100)

4 (57)

2 (7)

 < .001

 T2-weighted

     

  Hyperintense

23 (49)

1 (8)

5 (71)

17 (63)

.001

  Isointense

16 (34)

7 (54)

2 (29)

7 (26)

.21

  Hypointense

8 (17)

5 (39)

0 (0)

3 (11)

.10

Out-of-phase sequence signal drop

15 (32)

10 (77)

3 (43)

2 (7)

 < .001

  1. HCA, hepatocellular adenoma; H-HCA, HNF1α-inactivated HCA; bex3-HCA, β-catenin-exon-3-mutated HCA; I-HCA, inflammatory HCA; HCC, hepatocellular carcinoma; BMI, Body Mass Index; SD, standard deviation; bold typeface indicates statistical significance (p ≤ 0.05)
  2. aPercentage of female population only
  3. bPathology finding